New Method Developed for Growing Tissue Engineered Corneas
Sound of Science Podcasts
Fully Enabling Genome-Editing System for Crop Improvement Launched
Novel Tool Combines Computational Platform with a Portfolio of CRISPR 3.0 Genome-Editing Nucleases
Bioprocess Control Specialist Focuses on Single-Use Sensors
Lab Automation through Single-Use Sensors and Monitors
Lonza Upgrades Live-Cell Imaging System
For Obtaining Better Cell-Culture Analyses
For full access to this article login to GEN Select now.
Hopes Dashed for Alzheimer's Patients
The Latest Phase III Failure Perpetuates Skepticism about Developing Drugs for AD
- Hopes for a new drug to treat the symptoms of Alzheimer disease (AD) diminished again on March 3 when Pfizer and Medivation reported Phase III results showing that Dimebon failed to meet its co-primary and secondary efficacy endpoints. Pfizer had shelled out $225 million up front and agreed to ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.